Tiziana Life Sciences Ltd (FRA:0RP)

Germany flag Germany · Delayed Price · Currency is EUR
1.540
+0.010 (0.65%)
At close: Nov 28, 2025
73.03%
Market Cap184.45M
Revenue (ttm)n/a
Net Income (ttm)-10.93M
Shares Outn/a
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume10
Open1.540
Previous Close1.530
Day's Range1.540 - 1.540
52-Week Range0.615 - 2.140
Betan/a
RSI50.59
Earnings DateDec 26, 2025

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for u... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 9
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0RP
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.